Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-escalation, Dose-extension and Efficacy-extension, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of AP-L1898 Capsule for the Treatment of the Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT04993391 is registered in ClinicalTrials.gov with Suzhou Junjing BioSciences Co., Ltd. as lead sponsor.

NCT NCT04993391
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04993391 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-escalation, Dose-extension and Efficacy-extension, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of AP-L1898 Capsule for the Treatment of the Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Lead sponsor
Suzhou Junjing BioSciences Co., Ltd.
Phase
Phase 1/2
Overall status
Terminated
Start date
July 14, 2021
Completion date
February 4, 2024
Enrollment
32 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer